{
    "clinical_study": {
        "@rank": "82124", 
        "arm_group": [
            {
                "arm_group_label": "P2202", 
                "arm_group_type": "Active Comparator", 
                "description": "Two treatment arms in Stage I-  P2202 (1000 mg) and placebo\nFour treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Two treatment arms in Stage I-  P2202 (1000 mg) and placebo\nFour treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "It is a phase II, randomized, double-blind, placebo-controlled study of P2202 in patients of\n      type 2 diabetes mellitus, inadequately controlled with a stable dose of metformin or\n      sulfonylurea or both."
        }, 
        "brief_title": "A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 Diabetes", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "It is a phase II, prospective, randomized, double-blind, placebo-controlled, dose-ranging,\n      multi-centre, two-staged, fixed-design study of P2202 in patients of type 2 diabetes\n      mellitus, inadequately controlled with a stable dose of metformin or sulfonylurea or both.\n      This study will consist of accrual in Stage I (n=56/arm, which is 70% of the total sample\n      size required), followed by an interim analysis on completion of the treatment period, to\n      aid further decisions on accrual and dose selection in Stage II of the study, and completion\n      of Stage I."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who understand and are willing to give informed consent to participate in\n             the trial.\n\n          -  Adult male and female subjects between 18 years to 65 years of age with a BMI \u2265 27\n             kg/m2 \u2264 40 kg/m2, inclusively.\n\n          -  Subjects with established type 2 diabetes mellitus of at least 3 months duration at\n             the time of screening.\n\n          -  Subjects with an inadequate glycemic control defined by an HbA1c level of \u2265 7.5% and\n             \u226510% at screening.\n\n          -  Subjects who are on a stable dose of:\n\n               -  Metformin (up to 2.55 gm/day or maximum tolerated dose of at least 1 gm/day)\n                  and/or\n\n               -  Sulfonylurea (glimepiride \u2264 4 mg/day, gliclazide \u2264 160 mg, glibenclamide or\n                  glyburide \u2264 10 mg and glipizide \u2264 10 mg), for \u2264 2 months prior to the screening\n                  visit.\n\n          -  Subjects with fasting plasma glucose of \u226414.4 mmol/L (260 mg/dL) and at least 5.5\n             mmol/L or 100 mg/dL.\n\n        Exclusion Criteria:\n\n          -  Subjects who have type 1 diabetes mellitus, maturity-onset diabetes of the young or\n             any rare form of diabetes. Subjects with hyperglycemia due to secondary causes.\n\n          -  Subjects who have had more than 4 episodes of severe hypoglycemia in the 6 months\n             prior to screening.\n\n          -  Subjects with a history of acute diabetic complications\n\n          -  Subjects who have been treated with insulin (except for use of insulin for short term\n             management of acute conditions), thiazolidinediones, dual proliferator activated\n             receptors agonists, glucagon-like peptide analogues, dipeptidyl peptidase inhibitors\n             or 11bHSD-1 inhibitors in any form, in the 3 months prior to screening.\n\n          -  Subjects who are receiving systemic glucocorticoids (\u226514 days)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01674348", 
            "org_study_id": "P2202/47/10"
        }, 
        "intervention": [
            {
                "arm_group_label": "P2202", 
                "description": "Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus", 
                "intervention_name": "P2202", 
                "intervention_type": "Drug", 
                "other_name": "P2202"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Diabetes Mellitus", 
        "lastchanged_date": "August 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M4G 3E8"
                }, 
                "name": "LMC Endocrinolgy Centres Ltd"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Two-staged, Fixed Design Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Overweight/Obese Patients of Type 2 Diabetes Mellitus Inadequately Controlled on Metformin, Sulphonylurea, or Both.", 
        "other_outcome": {
            "description": "PK parameters derived will be maximum plasma concentration (Cmax), time at which Cmax is reached (Tmax), area under the plasma concentration curve calculated up to 24 hours (AUC 0-24h), area under the curve extrapolated to infinity (AUC 0-inf), elimination rate constant (Kel), volume of distribution (Vz), terminal elimination half life (t1/2) and protein binding.", 
            "measure": "Pharmacokinetic profile (Cmax, Tmax and AUC)", 
            "safety_issue": "No", 
            "time_frame": "Pre dose at Day 1 Week 1 till Week 12"
        }, 
        "overall_official": [
            {
                "affiliation": "Health Canada", 
                "last_name": "Dr. Ronnie Aronson, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Health Canada", 
                "last_name": "Dr. Robert Petrella, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Health Canada", 
                "last_name": "Dr. Naresh Aggarwal, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "India: Drugs Controller General of India"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The change in HbA1c from baseline till end of 12 weeks in patients of type 2 diabetes mellitus, in the P2202 arms as compared to placebo.", 
            "measure": "Change in HbA1c from baseline", 
            "safety_issue": "No", 
            "time_frame": "From baseline till end of 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01674348"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety assessment will be done by eliciting information regarding AEs including evaluation of hypoglycemic events, physical examination, vital signs assessment, 12-lead ECGs, clinical laboratory tests, markers of HPA axis function, plasma ACTH and free testosterone, plasma rennin and serum aldosterone and self-monitoring of blood glucose profiles.", 
            "measure": "Number of subjects with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "From screening to 3 weeks (\u00b1 1 week) after the last visit at the end of Week 12 or early exit visit"
        }, 
        "source": "Piramal Enterprises Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Piramal Enterprises Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013", 
        "why_stopped": "Due to non-recruitment, the study is being halted. There are no major safety or tolerability\n    concerns in the study conducted so far."
    }
}